![Nektar Therapeutics [NKTR] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/NKTR_48b210c33b.png)
Nektar Therapeutics (NKTR) faces a class action concerning disclosures around its REZOLVE-AA clinical trial, with focus on enrollment criteria and how certain deviations may have impacted trial outcomes and investor expectations.
Learn about securities lawsuits tied to your portfolio and recover money!
Nektar Therapeutics is facing a federal securities class action that centers on a single point of failure. The integrity of a clinical trial. Investors allege that the company misrepresented how its flagship REZOLVE-AA trial was conducted, creating a narrative of rigor and control that later unraveled.
The complaint, filed in the Northern District of California, alleges that between February 26, 2025 and December 15, 2025, Nektar and senior executives made materially false statements about trial enrollment compliance and clinical execution. When the truth emerged on December 16, 2025, the company disclosed that four ineligible patients had been included in the trial, which Nektar said contributed to the study’s failure to reach statistical significance, sending shares down nearly 8% in a single session.
“Most NKTR shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Nektar Therapeutics operates as a biopharmaceutical company focused on immune system modulation therapies. Its lead candidate, rezpegaldesleukin, targets autoimmune disorders and was positioned as a first-in-class regulatory T cell stimulator for alopecia areata.
The REZOLVE-AA Phase 2b trial was central to that strategy. Initiated in March 2024, it enrolled approximately 90 patients suffering from severe-to-very severe alopecia areata, with strict inclusion criteria tied to SALT scores and treatment history.
By early 2025, the company had completed enrollment and began reinforcing a narrative of disciplined execution. Executives repeatedly emphasized operational rigor and adherence to protocol. This was not a peripheral program. Rezpegaldesleukin was Nektar’s lead product candidate, and investor attention was closely tied to the REZOLVE-AA readout.
Throughout the class period, Nektar’s leadership presented the trial as tightly controlled and methodologically sound. Executives stated that patient eligibility was carefully screened and that the study design minimized operational risk. One executive noted that patients “had to present with severe-to-very-severe disease… for at least six months in order to be eligible for inclusion.” Another emphasized “unique operational features… designed to minimize clinical operational risk.”
SEC filings reinforced the same message. The company’s 2024 Form 10-K highlighted its “expertise to develop novel drug candidates” and certified that disclosures contained no material misstatements. Investors were told that the trial’s enrollment criteria and operational safeguards were being followed.
According to the complaint, it did not. Plaintiffs allege that enrollment did not follow protocol standards and that ineligible patients were admitted into the trial. This deviation was not trivial. According to the complaint, it affected the reliability of the trial’s results and the interpretation of its outcome.
The sequence is tight. Almost clinical in its progression.
February 26, 2025. Nektar announces completion of enrollment in the REZOLVE-AA trial, emphasizing strict eligibility criteria.
March through November 2025. Executives reiterate that the trial followed protocol and express optimism about upcoming results. SEC filings and earnings calls reinforce confidence in trial design and execution.
July 2025. The company completes a $115 million public stock offering, raising capital at a time when investor confidence remains intact.
December 16, 2025. The disclosure. Nektar announces topline results that fail to reach statistical significance. The company attributes the failure to the inclusion of four patients who should have been excluded from the study.
That detail matters. Four patients. Enough to tip the outcome.
The same disclosure reveals that excluding those patients would have produced statistically significant results.
The market reaction was immediate and precise.
On December 16, 2025, Nektar’s stock fell $4.14 per share, or 7.77%, closing at $49.16. The decline was directly tied to the disclosure regarding ineligible patients. Analysts moved quickly to assign causation. Piper Sandler noted that the stock was trading down due to “n=4 patients [who] had major study eligibility violations.” Other firms echoed the same conclusion, identifying trial integrity as the sole driver of the muted results and corresponding price drop.
The case is captioned Schramke v. Nektar Therapeutics, et al., filed in the United States District Court for the Northern District of California. The complaint asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Defendants include the company and senior executives, including the CEO, CFO, and Chief R&D Officer.
Scienter allegations focus on both motive and knowledge. The complaint highlights insider stock sales, including nearly $1 million in proceeds by the CEO during the class period. It also points to executive bonuses tied to trial progress and enrollment milestones, suggesting incentive alignment with positive disclosures.
The case is in its early stages, with class certification and lead plaintiff appointment still to come.
The immediate shareholder-facing takeaway was the market reaction to Nektar’s December 16, 2025 disclosure. According to the complaint, the company said four patients with major study eligibility violations had been included in the modified intent-to-treat population, and the stock fell $4.14, or 7.77%, to close at $49.16 that day. Public reporting on the disclosure likewise focused on the enrollment issue and the fact that both treatment arms would have met statistical significance if those four patients were excluded.
For investors evaluating the case, the key question is whether earlier statements about enrollment controls and protocol compliance accurately reflected how the trial was conducted.
Analyst coverage following the disclosure remained active and detailed.
Analyst reaction focused heavily on the four patients with major study eligibility violations. The complaint specifically quotes Piper Sandler as saying the stock was trading down because “n=4 patients had major study eligibility violations,” and quotes BTIG as saying the muted stock reaction was “explained solely by” those patients’ inclusion. Public reporting likewise centered on the enrollment issue and its impact on how investors interpreted the topline data. The split narrative was that the underlying drug signal remained of interest to some observers, while the enrollment errors raised serious questions about execution.
Nektar’s SEC filings during the class period emphasized its expertise in drug development and clinical execution. The 2024 Form 10-K repeatedly stated that the company used its “drug development expertise” to advance candidates through clinical trials. Executives certified that filings contained no material misstatements or omissions. The complaint alleges that these filings failed to disclose known issues with trial enrollment and protocol adherence. The complaint also alleges that these omissions implicated Item 303 of Regulation S-K, which requires disclosure of known trends or uncertainties reasonably likely to materially affect results.
The omitted risk was specific. Enrollment integrity. Not abstract. Not theoretical. Procedural.
This case turns on a detail that should not have been a detail. Clinical trials are built on inclusion criteria. Deviate from them, and the data shifts. Investors rely on those guardrails. When they fail, so does confidence.
The Nektar lawsuit reflects a recurring theme in biotech securities litigation: not just whether a drug shows promise, but whether the process used to evaluate it was described to investors accurately. For investors, the lesson is quiet but persistent.
Scrutinize not only outcomes, but methods. Pay attention to how companies describe operational controls. And when disclosures hinge on execution, assume the market will respond in kind.
The science may survive. The narrative rarely does.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
![Eos Energy Enterprises [EOSE] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/EOSE_480699100e.png)
Eos Energy (EOSE) faces a class action alleging it misled investors about its automated battery production and ability to meet revenue targets, with operational failures leading to a nearly 40% stock drop.
![ODDITY Tech Ltd. [ODD] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/ODD_2c26a8b9f9.png)
ODDITY Tech Ltd. (ODD) faces a class action alleging it concealed rising customer acquisition costs caused by advertising algorithm changes. The lawsuit claims the company misled investors about the strength of its digital model, leading to significant losses after a sharp stock decline.
![Trip.com Group Limited [TCOM] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/TCOM_d0b18dde74.png)
Trip.com Group Limited (TCOM) faces a class action alleging it misled investors by understating antitrust regulatory risks in China. The lawsuit claims the company framed active regulatory scrutiny as hypothetical, leading to investor losses after news of a probe triggered a sharp stock decline.